Ubiquitin enzymes, is also termed by E2 enzyme and seldom as known ubiquitin-carrier enzymes. This helps to achieve the second successive step in the ubiquitination process that aims at a protein to cut into various segments through the proteasome. The ubiquitination process firmly attaches ubiquitin, which is a short protein consisting of 76 amino acids, to a lysine deposit on the essential protein to be targeted. Once a protein gets attached with any of the ubiquitin moiety, excess rounds of ubiquitination form a polyubiquitin chain that is approved by the proteasome's 19S regulatory element.
Ubiquitin Enzyme will not only profit big pharma companies but also small to mid-sized players and academic institutions.
Globally, there are numerous studies and research groups trying to explain the unseen potential of extremely difficult regulatory structure in order to progress the viable drug compound. Many literatures studies in a short span of 1 year, nearly 1500 journals related to ubiquitin enzymes are being published since 2015. A number of procedural advances in ubiquitin enzyme had led to the enhancement and development of varied technological platforms, research based assessment, tool essentials, chemicals and pioneer compounds to help the different drug discovery programs in different academic and industry researchers. In fact, the current conclusive trend-lines from different literature studies explains that not only big pharma giants but also small scale to mid-sized players and academic institutions.
There are various strategic partnerships evolved and had linked various stakeholders to advance research and development processes in Ubiquitin Enzymes Market. The growing field of research has gained the attention of various venture capital firms and investors. The emerging market, mainly focus on cancer indication, is likely to flourish in the long term and observer the rise of several successful drugs.
Cancer under application segment to dominate the Ubiquitin Enzymes Market over the forecast period
The global ubiquitin enzymes market is segmented on the basis of product type, application and geography. On the basis of product type, the market is divided into E1 and E2 enzymes as therapeutic targets, E3 enzymes as therapeutic targets, dub enzymes as therapeutic targets and associated drug class. On the basis of application, the Ubiquitin Enzymes Industry is divided into cancer, biological engineering and others.
Increase in clinical trial success rate pushes pharmaceutical industries to invest more in ubiquitin enzyme studies
Regional segmentation of the ubiquitin enzymes market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in the global ubiquitin enzymes market mainly due to increase in more number of research centers and presence of global pharma players which develop protein molecules for therapeutic activity process.
More than 40 clinical trial molecules in pipeline is expected to boost growth of Ubiquitin Enzymes Market
Key players operating the ubiquitin enzymes market include 3SBio, 5AM Ventures, Abbiotec, Abcam, AcelRx Pharmaceuticals, Aegera Therapeutics, Aeneas Ventures, Agilis Biotherapeutics, Aileron Therapeutics, Alexion Pharmaceuticals and Amgen among others. Major market players are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, ubiquitin pathway based inhibitors, there are over 45 molecules that are under development which are used to treat a variety of indications. Considering the disturbingly high incidence rate of cancer across the globe, the ubiquitin enzymes market is expected to ride on a wave of positive growth in the foreseeable future.
Research and development activities related to ubiquitin enzymes is expected to boost the market growth. For instance, in March 2019, researchers from Sungkyunkwan University School of Medicine reported that suppression of ubiquitin pathway by small molecule binding to ubiquitin increases doxorubicin sensitivity of the cancer cells.
In November 2018, researchers from Institut national de la recherche agronomique found that Ubiquitin-conjugating enzyme E2 E1 Is preferentially expressed in the cytoplasm of slow-twitch fibers and protects skeletal muscles from exacerbated atrophy upon dexamethasone treatment.
In March 2018, researchers from Chinese Academy of Tropical Agricultural Sciences found a total of 40 putative ubiquitin-conjugating enzyme genes. The genes were grouped into 15 groups based on a phylogenetic analysis.